South Street Advisors LLC lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 19.4% during the third quarter, Holdings Channel.com reports. The firm owned 186,531 shares of the company’s stock after selling 44,988 shares during the quarter. Novo Nordisk A/S makes up about 3.4% of South Street Advisors LLC’s investment portfolio, making the stock its 8th biggest position. South Street Advisors LLC’s holdings in Novo Nordisk A/S were worth $22,210,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Orion Capital Management LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. Gilliland Jeter Wealth Management LLC raised its stake in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its position in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
Shares of NVO stock traded down $3.58 during trading hours on Friday, reaching $101.74. The company had a trading volume of 8,076,248 shares, compared to its average volume of 4,457,389. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The company has a market capitalization of $456.56 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a fifty day moving average of $118.58 and a 200-day moving average of $129.58.
Wall Street Analyst Weigh In
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- What Makes a Stock a Good Dividend Stock?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Quiet Period Expirations Explained
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What are earnings reports?
- Time to Load Up on Home Builders?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.